



May 21, 2024

The Manager- Listing BSE Limited Corporate Relationship Dept., 5th Floor, New Trading Ring Rotunda Building, P J Towers, Dalal Street, Fort Mumbai - 400001

The Manager- Listing **National Stock Exchange of India Limited** Exchange Plaza, 5th Floor, Plot No. C/1, G Block Bandra –Kurla Complex, Bandra (E) Mumbai - 400051

Dear Sir,

<u>Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements)</u> <u>Regulation, 2015</u>

This is to inform that AstraZeneca Pharma India Limited had vide its letter dated August 16, 2018 informed the receipt of marketing authorization for Olaparib (Lynparza) 100mg and 150 mg tablets which was also indicated for the treatment of patient with gBRCA mutation and advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.

Through this letter we wish to inform that the Company has now received permission for voluntary withdrawal of the above-mentioned indication of Olaparib (Lynparza) 100mg and 150 mg tablets from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India.

We request you to take the above intimation on record.

Thanking you Yours faithfully

For AstraZeneca Pharma India Limited

Manasa. R Company Secretary

CORPORATE & REGD. OFFICE AstraZeneca Pharma India Ltd. P. B. No. 4525, Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore - 560 045, INDIA
 TEL
 : +91 80 6774 8000

 FAX
 : +91 80 6774 8857

 CIN
 : L24231KA1979PLC003563

WEB : www.astrazeneca.com/india

FACTORY 12th Mile on Bellary Road Venkatala, Kattigenahalli Village Yelahanka Bangalore - 560 063 INDIA

TEL : +91 80 6774 9000

FAX : +91 80 2846 2208 +91 80 6774 9628